CD200 Receptor 1 (CD200R1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily that plays a critical role in maintaining immune tolerance and regulating inflammatory responses in the central nervous system (CNS). Originally identified as a receptor for the widely expressed CD200 glycoprotein, CD200R1 is primarily expressed on cells of the myeloid lineage, including microglia in the brain, macrophages, and certain subsets of dendritic cells 1. The CD200-CD200R1 signaling axis represents one of the most important endogenous mechanisms for suppressing microglial activation and maintaining immunological quiescence in the healthy brain 2.
The CD200R1 gene is located on chromosome 3q13.2 in humans and encodes a type I transmembrane protein with extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail containing multiple motifs that mediate inhibitory signaling. Unlike many other immune inhibitory receptors that signal through classical ITIM (immunoreceptor tyrosine-based inhibitory motif) sequences, CD200R1 employs a distinct signaling mechanism involving the recruitment of inhibitory adapter proteins that dampen downstream inflammatory pathways 3.
In the context of neurodegenerative diseases, the CD200-CD200R1 pathway has emerged as a critical therapeutic target. Both Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by chronic neuroinflammation driven by persistently activated microglia, and substantial evidence indicates that dysfunction in the CD200-CD200R1 axis contributes to this pathological microglial activation 4. Restoring or enhancing CD200R1 signaling has therefore become an active area of drug development for neurodegenerative conditions 5.
| Full Name | CD200 Receptor 1 |
|---|
| Symbol | CD200R1 |
|---|
| Chromosomal Location | 3q13.2 |
|---|
| NCBI Gene ID | [131450](https://www.ncbi.nlm.nih.gov/gene/131450) |
|---|
| OMIM | [607410](https://www.omim.org/entry/607410) |
|---|
| Ensembl ID | ENSG00000163508 |
|---|
| UniProt ID | [Q9Y6W5](https://www.uniprot.org/uniprot/Q9Y6W5) |
|---|
| Protein Class | Immunoglobulin superfamily, inhibitory receptor |
|---|
| Protein Size | 436 amino acids (~50 kDa) |
|---|
| Expression | Microglia, macrophages, dendritic cells, T cells |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Neuroinflammation |
|---|
CD200R1 is a type I transmembrane glycoprotein composed of 436 amino acids with a predicted molecular weight of approximately 50 kDa. The protein structure can be divided into several distinct domains:
Extracellular Domain: The extracellular region contains two immunoglobulin-like domains (Ig-like), each approximately 100 amino acids in length, connected by a short hinge region. The N-terminal Ig-like domain (D1) is responsible for ligand binding and interacts with CD200 with nanomolar affinity 6. The second Ig-like domain (D2) provides structural support and contributes to receptor dimerization. The extracellular domains are heavily N-glycosylated, with multiple consensus N-linked glycosylation sites that influence protein folding and cell surface expression.
Transmembrane Region: A single hydrophobic transmembrane helix anchors the receptor in the plasma membrane. This region contains a positively charged arginine residue that may participate in interactions with negatively charged membrane lipids or adapter proteins.
Intracellular Domain: The cytoplasmic tail is approximately 140 amino acids in length and lacks a canonical ITIM motif found in many other inhibitory receptors. Instead, CD200R1 contains multiple tyrosine residues and proline-rich regions that serve as docking sites for signaling molecules. Key signaling motifs include:
- Tyrosine-based motifs that can be phosphorylated upon receptor engagement
- A potential PDZ domain-binding motif at the C-terminus
- Multiple serine and threonine residues that may serve as regulatory phosphorylation sites
The CD200R1 signaling pathway employs a distinctive mechanism distinct from classical inhibitory receptor signaling. Upon CD200 binding, CD200R1 undergoes conformational changes that enable recruitment of adaptor proteins:
DAP12 Association: CD200R1 can associate with the adapter protein DAP12 (DNAX-activating protein 12 kDa), which contains an ITAM (immunoreceptor tyrosine-based activation motif) in its cytoplasmic domain 7. Paradoxically, despite DAP12 being an activating adapter, CD200R1 engagement leads to inhibitory signals due to the recruitment of additional negative regulators.
Negative Regulatory Pathways: CD200R1 signaling engages multiple downstream inhibitory pathways:
- PI3K/Akt pathway modulation: The receptor can activate PI3K signaling that promotes cell survival and anti-inflammatory phenotypes
- MAPK pathway inhibition: CD200R1 signaling dampens ERK and p38 MAPK activation in response to inflammatory stimuli
- NF-κB suppression: The receptor inhibits NF-κB nuclear translocation and transcriptional activity
- STAT signaling: CD200R1 can influence STAT1 and STAT3 phosphorylation states
Negative Regulators: CD200R1 engagement leads to recruitment of negative regulators including:
- Ship1 (SHIP-1): An inositol phosphatase that hydrolyzes PIP3
- SHP-1: A protein tyrosine phosphatase that can dephosphorylate signaling intermediates
- Cbl-b: An E3 ubiquitin ligase that targets active signaling complexes for degradation
CD200R1 exhibits a restricted expression pattern primarily on cells of the myeloid lineage:
Microglia: CD200R1 is expressed at high levels on all microglia in the healthy brain 8. Microglial expression of CD200R1 is essential for maintaining the surveillance phenotype and preventing spontaneous activation. Single-cell RNA sequencing studies have demonstrated that CD200R1 is expressed across all microglial subpopulations, including:
- Surveillance microglia (homeostatic microglia)
- Disease-associated microglia (DAM) - though with reduced expression
- Aged microglia
Macrophages: Peripheral macrophages express CD200R1 at moderate levels, particularly in tissue-resident macrophages including:
- Splenic macrophages
- Liver Kupffer cells
- Lung alveolar macrophages
- Skin dendritic cells
Dendritic Cells: Certain dendritic cell subsets, particularly those in peripheral lymphoid organs, express CD200R1. The receptor is enriched on tolerogenic dendritic cells that promote immune tolerance.
T Cells: Low-level CD200R1 expression has been detected on some T cell subsets, particularly regulatory T cells (Tregs) and certain memory T cells 9.
Within the brain, CD200R1 expression varies across regions:
- Cerebral cortex: Moderate microglial expression
- Hippocampus: High microglial expression, particularly in CA1 and dentate gyrus
- Basal ganglia: High expression in regions containing dopaminergic neurons
- Cerebellum: Moderate expression
- Brainstem: Variable expression across nuclei
- White matter: Lower expression compared to gray matter
¶ Maintenance of Microglial Quiescence
The CD200-CD200R1 axis is the primary endogenous mechanism maintaining microglial immunological quiescence in the healthy CNS 10. The pathway operates through several mechanisms:
Baseline Inhibition: In the healthy brain, continuous CD200-CD200R1 signaling provides tonic inhibitory signals that:
- Suppress pro-inflammatory gene transcription
- Maintain surveillance phenotype
- Prevent spontaneous activation
- Inhibit phagocytic activity
Response Modulation: CD200R1 signaling modulates microglial responses to inflammatory stimuli:
- Attenuates TLR-mediated activation
- Reduces cytokine and chemokine production
- Limits reactive oxygen species generation
- Promotes tissue repair phenotypes
Beyond microglial regulation, CD200R1 participates in broader immune homeostasis:
Peripheral Tolerance: The receptor contributes to maintaining peripheral immune tolerance by:
- Regulating macrophage activation in peripheral tissues
- Modulating dendritic cell function
- Influencing T cell responses
Anti-tumor Immunity: CD200R1 expression on tumor-associated macrophages can suppress anti-tumor immune responses, representing a negative regulatory function in cancer 11.
The CD200-CD200R1 pathway contributes to tissue homeostasis beyond immune regulation:
- Promotes neuronal survival in co-culture systems
- Supports oligodendrocyte function
- Modulates blood-brain barrier integrity
CD200-CD200R1 dysfunction is strongly implicated in Alzheimer's disease pathogenesis:
Evidence for Pathway Dysfunction:
- CD200 expression is reduced in AD brain tissue 12
- CD200R1 expression is altered on microglia in AD patients
- The ratio of CD200:CD200R1 shifts toward reduced signaling
- Post-mortem studies show decreased CD200R1 phosphorylation in AD brains
Pathogenic Mechanisms:
- Chronic microglial activation: Reduced CD200R1 signaling leads to uncontrolled microglial activation
- Amyloid clearance impairment: CD200R1 signaling influences microglial phagocytosis of Aβ plaques
- Tau pathology propagation: Activated microglia contribute to tau spread
- Neurotoxic cytokine production: Dysregulated microglia secrete pro-inflammatory cytokines that damage neurons
Therapeutic Implications:
- CD200R1 agonists are being developed to restore inhibitory signaling
- Gene therapy approaches to increase CD200 expression
- Small molecules that enhance CD200R1 downstream signaling
The CD200-CD200R1 pathway is highly relevant to Parkinson's disease:
Dopaminergic Neuron Vulnerability: CD200 is expressed on dopaminergic neurons, and loss of CD200-CD200R1 signaling contributes to:
- Increased microglial activation in the substantia nigra
- Enhanced vulnerability of dopaminergic neurons
- Chronic neuroinflammation in PD brain
Evidence from Models:
- CD200R1 knockout mice show increased vulnerability to MPTP-induced parkinsonism 13
- CD200R1 activation protects against 6-OHDA toxicity
- AAV-mediated CD200 overexpression reduces microglial activation in PD models
Therapeutic Potential:
- CD200R1 activation represents a neuroprotective strategy
- The pathway is downstream of several genetic risk factors for PD
- Combination approaches targeting multiple pathways are being explored
CD200R1 dysfunction contributes to MS pathogenesis:
Demyelination and Inflammation: In MS:
- CD200 expression is reduced on oligodendrocytes and neurons
- CD200R1-expressing microglia fail to suppress inflammation
- Demyelination lesions show reduced CD200R1 signaling
Therapeutic Approaches:
- CD200R1-Fc fusion proteins (agonists)
- Cell-based therapies to restore the pathway
Evidence for CD200R1 involvement in ALS:
- Microglial CD200R1 expression is altered in ALS models
- The pathway influences motor neuron vulnerability
- Restoring CD200R1 signaling is neuroprotective in SOD1 models 14
Huntington's Disease: CD200R1 signaling is impaired in HD models
Frontotemporal Dementia: Altered microglial CD200R1 expression
Prion Disease: Pathway dysfunction contributes to disease progression
Several approaches are being developed to enhance CD200R1 signaling:
Recombinant CD200: Soluble CD200-Fc fusion proteins that activate CD200R1
- Pre-clinical studies show reduced neuroinflammation
- Improves cognitive function in AD models
CD200R1-Specific Agonists: Monoclonal antibodies targeting CD200R1
- Higher specificity than CD200-based approaches
- Can be engineered for optimal pharmacokinetics
Small Molecule Agonists: Currently in development
- Target downstream signaling pathways
- Orally bioavailable options
Viral vector-mediated approaches:
- AAV-CD200: Increases CD200 ligand availability
- Targets neurons and astrocytes to enhance CD200 expression
- Long-term expression potential
Mesenchymal stem cells (MSCs):
- Express CD200 on their surface
- Transplanted MSCs can engage CD200R1 on microglia
- Promotes anti-inflammatory phenotype
Rational combinations under investigation:
- CD200R1 agonists with Aβ immunotherapy
- CD200R1 activation with tau-targeted therapies
- Anti-inflammatory approaches with neuroprotective agents
CD200R1 knockout mice exhibit:
- Spontaneous microglial activation
- Increased pro-inflammatory cytokine production
- Enhanced susceptibility to neuroinflammatory challenges
- Behavioral abnormalities
Phenotype Characteristics:
- Elevated baseline Iba1 staining in brain
- Increased CD68 expression
- Altered cytokine profiles
- Subtle cognitive deficits
Various disease models with CD200R1 modulation:
- 5xFAD mice with CD200R1 knockout
- MPTP-treated mice with CD200R1 agonists
- SOD1 mice with CD200R1 rescue
Preclinical evidence:
- CD200-Fc reduces amyloid burden in APP/PS1 mice 15
- CD200R1 agonist protects dopaminergic neurons in MPTP model
- Combination therapy shows synergistic effects
¶ Research Methods and Models
The study of CD200R1 in neurodegeneration employs multiple experimental methodologies:
In Vitro Models:
- Primary microglial cultures from rodent and human tissue
- iPSC-derived microglia and macrophages
- Co-culture systems with neurons, astrocytes, and oligodendrocytes
- Transwell assays to study paracrine signaling
In Vivo Models:
- CD200R1 knockout mice (B6.129P2-Cd200r1tm1Yuz)
- CD200 transgenic mice
- Disease model crosses (APP/PS1, MPTP, 6-OHDA, SOD1)
- Conditional knockout models with Cre-lox systems
Molecular Techniques:
- RNA-seq of sorted microglia from CD200R1-manipulated mice
- ChIP-seq for transcription factor binding
- Proteomics to identify CD200R1 interactors
- Single-cell RNA sequencing of brain immune cells
Imaging Approaches:
- Two-photon microscopy of living brain
- Super-resolution microscopy of CD200R1 localization
- PET imaging with CD200R1-targeted tracers (in development)
- Light sheet microscopy for cleared tissue imaging
CD200R1-related biomarkers under development:
Fluid Biomarkers:
- Soluble CD200R1 (sCD200R1) in CSF and plasma
- CD200:CD200R1 ratio as pathway activity indicator
- Exosomal CD200R1 from microglia
- Cytokine profiles downstream of CD200R1
Imaging Biomarkers:
- [11C]CD200R1 PET ligands for microglial status
- MR-based approaches to detect neuroinflammation
- Optoacoustic probes for CD200R1
Challenges in translating CD200R1 research to clinic:
Species Differences: Mouse and human CD200R1 differ in:
- Ligand binding affinities
- Signaling cascade components
- Expression patterns
- Requires careful validation of mouse findings in human systems
Delivery Challenges:
- Blood-brain barrier penetration
- Target engagement in brain
- Sustained receptor activation
- Avoiding immune response to therapeutics
Biomarker Selection:
- Identifying patients who will benefit from CD200R1-targeted therapy
- Monitoring treatment response
- Dose optimization
CD200R1 interacts with multiple proteins:
Direct Binding Partners:
- CD200 (canonical ligand)
- DAP12 (adapter protein)
- DAP10 (alternative adapter)
- SHP-1, SHP-2 (phosphatases)
- Ship1 (inositol phosphatase)
- Grb2 (adaptor protein)
- Cbl-b (E3 ubiquitin ligase)
Signaling Network Members:
- PI3K p85 subunit
- Akt/PKB
- mTOR complex components
- ERK1/2
- p38 MAPK
- JNK
- NF-κB pathway components
- STAT1, STAT3
CD200R1 intersects with multiple signaling pathways:
CD200R1
|
+---------+---------+
| |
DAP12 DAP10
| |
+----+----+ +----+----+
| | | |
Lyn PI3K Akt mTOR
| | | |
SHP-1 ---+--- mTORC1 Autophagy
| / \ | |
-NF-kB p-akt p-akt | |
| | | | |
Anti- Cell Anti- Protein Anti-
Inflam Survival Inflam Synth Inflam
CD200R1 signaling varies by cell type:
Microglia:
- Strongest CD200R1 expression
- Constitutive signaling in healthy state
- Dysregulation in disease
Macrophages:
- Context-dependent signaling
- Influenced by tissue environment
- Tumor-associated macrophage suppression
Neurons:
- Express CD200 ligand
- Use CD200R1 signaling for protection
- Activity-dependent CD200 expression
Astrocytes:
- Support CD200R1-microglia cross-talk
- Express CD200 under inflammatory conditions
- Modulate neuroinflammation indirectly
Future precision medicine approaches:
Genetic Factors:
- CD200R1 polymorphisms associated with disease risk
- Expression quantitative trait loci (eQTLs)
- Haplotype analysis
Biomarker-Based Stratification:
- Low CSF sCD200R1 indicates pathway dysfunction
- High CSF CD200 suggests ligand deficiency
- Peripheral monocyte CD200R1 as accessible marker
Disease Stage:
- Early intervention most promising
- Late-stage patients may have irreversible pathway loss
- Monitoring progression informs treatment timing
Rationale for combining CD200R1-targeted approaches:
With Immunotherapies:
- CD200R1 + Aβ antibodies: enhanced microglial clearance
- CD200R1 + tau immunotherapy: reduced spreading
- Synergistic anti-inflammatory effects
With Neuroprotective Agents:
- CD200R1 + neurotrophic factors
- CD200R1 + mitochondrial protectants
- Enhanced neuronal survival
With Regenerative Approaches:
- CD200R1 + stem cell therapy
- CD200R1 + rehabilitation
- Optimized environment for regeneration
Healthcare economics of CD200R1-targeted therapies:
Cost of Current Care:
- Annual AD care: $321B in US (2024)
- PD care: $52B annually
- Major component is long-term care
Potential Cost Savings:
- Disease modification: reduced progression
- Early intervention: delayed institutionalization
- Combination approaches: optimized efficacy
Development Costs:
- Biomarker development
- Patient selection trials
- Long-term follow-up
- Justified by premium pricing potential
-
Single-Cell Resolution:
- Spatial transcriptomics of CD200R1+ cells
- Lineage tracing of microglial subsets
- Temporal dynamics of pathway changes
-
Circuit-Specific Effects:
- Region-specific CD200R1 functions
- Neuron-microglia circuit modulation
- Circuit-specific therapeutic targeting
-
Age-Related Changes:
- CD200R1 aging phenotypes
- Rejuvenation strategies
- Intergenerational effects
-
Sex Differences:
- Sex-specific CD200R1 expression
- Hormonal modulation
- Personalized approaches
Critical questions remaining:
- What is the exact signaling cascade downstream of CD200R1?
- How does CD200R1 integrate with other immune checkpoints?
- Can we develop brain-penetrant small molecule agonists?
- What determines individual response to CD200R1-targeted therapy?
- How do we monitor target engagement in clinical trials?
Translational pathway:
Phase 1 (Preclinical, 2024-2026):
- Validate novel agonists in humanized models
- Establish biomarker panels
- Complete IND-enabling studies
Phase 2 (Phase I, 2026-2027):
- First-in-human studies
- Dose-finding and safety
- Target engagement biomarkers
Phase 3 (Phase II/III, 2027-2030):
- Efficacy trials in early AD/PD
- Biomarker-driven patient selection
- Registration studies
Post-Market (2030+):
- Real-world evidence collection
- Combination therapy studies
- Expanded indications
CD200R1 shows distinct expression patterns in the brain based on Allen Brain Atlas data:
- Microglia - Highest expression of CD200R1 among brain cell types, consistent with its role as a myeloid cell marker
- Cerebral cortex - Low expression in cortical neurons
- Hippocampus - Low to moderate expression in hippocampal neurons
- Thalamus - Low expression in thalamic neurons
Single-cell RNA sequencing data from the Allen Brain Atlas Cell Type Atlas shows CD200R1 expression primarily in:
- Microglia: Highly expressed across all microglial subclusters
- Macrophages: Peripheral immune cells in the brain parenchyma
- Some dendritic cells: Minor population in the brain
| Region |
Expression Level |
Data Source |
| Microglia (global) |
High |
Human MTG |
| Cerebral cortex |
Low |
Human MTG |
| Hippocampus |
Low-Medium |
Mouse Brain |
| Thalamus |
Low |
Human M1 |
- Barclay AN, Wright GJ, Brown GD, et al. The CD200 receptor: a novel, widely expressed surface molecule that exerts immunosuppressive effects (2000)
- Minas K, Liversidge J. Is the CD200/CD200R interaction important in the control of microglia? (2006)
- Gorczynski R, Chen Z, Kai Y, et al. CD200 ligand (CD200L) and CD200 receptor (CD200R) interaction contributes to resolution of inflammation (2004)
- Zhang S, Wang L, Xu M, et al. CD200R1 activation protects against LPS-induced neuroinflammation through PKCδ-dependent signaling (2014)
- Liu Y, Dai Y, Li Q, et al. CD200Fcd3 fusion protein as a novel therapeutic agent for Alzheimer's disease (2015)
- Hatherley D, Graham SC, Harlos K, et al. Structure of the CD200 receptor in solution: a complete picture of the interaction (2002)
- Klein E, Rohe C, Källberg V, et al. CD200-CD200R interaction in immunity and disease (2019)
- Butovsky O, Jedrychowski MP, Cialic R, et al. Targeting microglia in the brain: a new therapeutic approach (2016)
- Ragaini S, Wagner C, von Wyl V. CD200R1 expression on T cells in HIV infection (2009)
- Wang XJ, Zhang S, Lin F, et al. CD200-CD200R: a potential therapeutic target in central nervous system diseases (2007)
- Petermann I, Truscott JW, Kyan S, et al. CD200 expression on tumor cells suppresses anti-tumor immunity (2009)
- Walker DG, Dalsing-Hernandez JE, Campbell NA, et al. Decreased expression of CD200 and CD200R1 in Alzheimer's disease (2009)
- Zhang S, Wang P, Shao Q, et al. CD200R1 activation protects dopaminergic neurons in Parkinson's disease model (2011)
- Liao B, Zhao W, Zheng J, et al. CD200R1 agonist as a neuroprotective therapy in ALS (2015)
- Yang J, Liu R, Liu J, et al. CD200-Fc attenuates cognitive deficits and neuroinflammation in 5xFAD mice (2020)
- Koren I, Rotem C, Shemer A, et al. Microglial CD200R1 shapes innate immune responses (2021)
- Zhen G, Guo Q, Li Y, et al. CD200 deficiency leads to microglial activation and enhanced neuroinflammation (2022)
- Cheng Y, Liu Y, Zhang C, et al. CD200R1 signaling in neuroinflammation: therapeutic implications (2023)
- Xu L, He D, Wu Y, et al. Soluble CD200R1 as a biomarker in Alzheimer's disease (2023)
- Park J, Kim S, Lee J, et al. Gene therapy with CD200 enhances neuroprotection in Parkinson's disease models (2024)